OriGene Awarded Contract to Develop Monoclonal Antibodies for SISCAPA Monday, January 11, 2016 OriGene Technologies have announced that they have been awarded a Phase II SBIR contract from the National Cancer Institute (NCI) to develop high-affinity, anti-peptide antibodies for mass-spectrometry-based serum biomarker detection/ quantification assays. Pfizer, Adaptive Biotechnologies Collaborate Monday, January 11, 2016 Pfizer Inc. and Adaptive Biotechnologies Corporation have entered into a translational research collaboration to leverage next generation sequencing of the adaptive immune system to advance Pfizer’s growing immuno-oncology franchise. Aelix Therapeutics Raises €11.5M for Therapeutic HIV Vaccine Monday, January 11, 2016 Funds will support proof of concept studies for lead candidate HTI immunogen as a therapeutic vaccine against HIV infection.Study Shows Blocking Brain Inflammation Could Help Alzheimer's Saturday, January 09, 2016 The research was jointly funded by the Medical Research Council (MRC) and Alzheimer’s Research UK.Antibiotics Pave Way for C. Diff Infections Friday, January 08, 2016 New research from North Carolina State University and the University of Michigan finds that bile acids which are altered by bacteria normally living in the large intestine inhibit the growth of Clostridium difficile,or C. diff. C. diff is a harmful bacterium that can cause painful and sometimes fatal infections. Takeda Acquires U.S. Biologics Manufacturing Facility Thursday, January 07, 2016 Takeda Pharmaceutical Company Limited has announced the acquisition of a biologics manufacturing facility located in Brooklyn Park, Minnesota, U.S., from Baxalta US Inc.Complix Launches Strategic Collaboration with Merck Thursday, January 07, 2016 Complix to receive upfront fees, research funding, and milestone payments.Flu Virus Hijacking Tactics Revealed Thursday, January 07, 2016 Scientists at Imperial College London have discovered how flu viruses 'hijack' cell machinery when they infect the body. Preventing HER2+ Breast Cancer Recurrence Wednesday, January 06, 2016 Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient’s immune system – a weakness that in principle could be corrected with a HER2-targeted vaccine – according to a new study from the Perelman School of Medicine at the University of Pennsylvania.